Skip to main content
Clinical Trials/NCT05461755
NCT05461755
Completed
Phase 2

Treatment of Striae Distensae With Fractional Radiofrequency and Topical Tretinoin: An Intra-individual Study With Blinded Outcome Assessment

Merete Haedersdal1 site in 1 country20 target enrollmentStarted: November 22, 2022Last updated:

Overview

Phase
Phase 2
Status
Completed
Sponsor
Merete Haedersdal
Enrollment
20
Locations
1
Primary Endpoint
Improvement in appearance of striae with GAIS

Overview

Brief Summary

The study aims to explore the potential of combination therapy with fractional radiofrequency and topical tretinoin for treatment and overall improvement of striae albae. We also aim to assess subject satisfaction, local skin responses and adverse effects/reactions in relation to the treatments, alone and in combination.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Masking Description

Primary outcome assessment is blinded

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Subject has provided written informed consent
  • Subject is 18 years of age or older
  • Fitzpatrick skin type I-III
  • Striae albae (grade II-IV) ≥1 year of age and ≥ 4 lesions with a length of ≥ 2 cm each
  • Women of childbearing potential are not pregnant (confirmed by a negative u-HCG prior to study treatments) and use a safe contraceptive method prior to treatments.

Exclusion Criteria

  • Severe concurrent conditions such as cardiac disorders or poorly regulated diabetes
  • History of skin disorders such as keloids, abnormal wound healing or very fragile skin
  • History of heat-stimulated disease such as herpes simplex in the treatment area
  • History of bleeding coagulopathies or use of anti-coagulants
  • Surgery in the treatment area past 6 months or before complete healing
  • Tattoo or permanent make-up in treatment area
  • Excessively tanned skin from sun, tanning bed or tanning creams last 2 weeks
  • Dermabrasion, resurfacing, soft tissue/fat injections or chemical peeling in treatment area the past 3 months
  • Abnormal skin (e.g. rash, infection, dermatitis) at the treatment area at the time of inclusion
  • Treatment with Isotretinoin within the past 6 months

Arms & Interventions

Combination therapy: Fractional radiofrequency and topical tretinoin

Experimental

3 study treatments: at baseline, 1-month, 2-month with subsequent application of topical tretinoin. Home application of tretinoin between study visits

Intervention: Fractional radiofrequency and topical Tretinoin (Combination Product)

Fractional radiofrequency

Active Comparator

3 study treatments: at baseline, 1-month, 2-month

Intervention: Fractional radiofrequency (Device)

Topical tretinoin

Active Comparator

Application at study visits and home application between study visits

Intervention: Topical Tretinoin (Drug)

Outcomes

Primary Outcomes

Improvement in appearance of striae with GAIS

Time Frame: Baseline, at 4 weeks, 8 weeks and 20 weeks follow-up

Standardized clinical photos from baseline and follow-up comparing treatments and assessed by blinded evaluator on the Global Aesthetic Improvement Scale (GAIS)

Secondary Outcomes

  • Evaluation of striae with POSAS(Baseline - 20 weeks follow-up (12 weeks after last treatment))
  • Evaluation of striae with imaging(Baseline, at 4 weeks, 8 weeks and 20 weeks follow-up)
  • Safety: LSR and AE/AR(Baseline, at 4 weeks, 8 weeks and 20 weeks follow-up)
  • Subject satisfaction(Baseline - 20 weeks follow-up (12 weeks after last treatment))

Investigators

Sponsor
Merete Haedersdal
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Merete Haedersdal

Consultant in Dermatology, Clinical Professor

Bispebjerg Hospital

Study Sites (1)

Loading locations...

Similar Trials